Arlocabtagene autoleucel vs CAR-GPRC5D (RD118, IASO Biotherapeutics)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: GPRC5D · full Multiple Myeloma pipeline
Arlocabtagene autoleucel
Developed by Bristol-Myers Squibb and partners
NCT04674813 · Phase 1 · completed
Everyone enrolled knowingly received the therapy, with no random assignment and no comparison group, so response and safety data cannot be separated from how this particular group of patients would have fared anyway. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT06615479 (registry estimate)
Reported efficacy
Number of participants with Adverse Events (AEs) (Up to 2 years after CC-95266 infusion); Number of participants with significant laboratory abnormalities (Up to 2 years after CC-95266 infusion); Number of participants with Dose Limiting Toxicities (DLTs) (Up to 2 years after CC-95266 infusion); Maximum Tolerated Dose (MTD) (Up to 2 years after CC-95266 infusion); Recommended Phase 2 Dose (RP2D) (Up to 2 years after CC-95266 infusion): In 79 efficacy-evaluable patients with heavily pretreated relapsed/refractory multiple myeloma (median 5 prior regimens), the overall response rate was 87%, comprising a 53% complete response rate, a 23% very good partial response rate and an 11% partial response rate.
Result source: NCT04674813
CAR-GPRC5D (RD118, IASO Biotherapeutics)
Developed by IASO Biotherapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Arlocabtagene autoleucel | CAR-GPRC5D (RD118, IASO Biotherapeutics) |
|---|---|---|
| PFS, median | —Trial running · NCT06615479 | —Not reported |
| OS, median | —Trial running · NCT06615479 | —Not reported |
| ORR | —Trial running · NCT06615479 | —Not reported |
| VGPR or better | —Trial running · NCT06615479 | —Not reported |
| MRD negativity | —Trial running · NCT06615479 | —Not reported |
PFS, median
- Arlocabtagene autoleucel
- —Trial running · NCT06615479
- CAR-GPRC5D (RD118, IASO Biotherapeutics)
- —Not reported
OS, median
- Arlocabtagene autoleucel
- —Trial running · NCT06615479
- CAR-GPRC5D (RD118, IASO Biotherapeutics)
- —Not reported
ORR
- Arlocabtagene autoleucel
- —Trial running · NCT06615479
- CAR-GPRC5D (RD118, IASO Biotherapeutics)
- —Not reported
VGPR or better
- Arlocabtagene autoleucel
- —Trial running · NCT06615479
- CAR-GPRC5D (RD118, IASO Biotherapeutics)
- —Not reported
MRD negativity
- Arlocabtagene autoleucel
- —Trial running · NCT06615479
- CAR-GPRC5D (RD118, IASO Biotherapeutics)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Arlocabtagene autoleucel: no structured comparison results are available for Multiple Myeloma.
CAR-GPRC5D (RD118, IASO Biotherapeutics): no structured comparison results are available for Multiple Myeloma.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Arlocabtagene autoleucel's landscape · CAR-GPRC5D (RD118, IASO Biotherapeutics)'s landscape